Page last updated: 2024-08-26

mafosfamide and Minimal Disease, Residual

mafosfamide has been researched along with Minimal Disease, Residual in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (100.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Rowley, SD	1
Campanini, E; Fogli, M; Fortuna, A; Lemoli, RM; Mangianti, S; Motta, MR; Ratta, M; Rizzi, S; Tura, S	1

Other Studies

2 other study(ies) available for mafosfamide and Minimal Disease, Residual

Article	Year
Bone marrow purging, 4-hydroperoxycyclophosphamide, and the FDA. Journal of hematotherapy, 1993,Fall, Volume: 2, Issue:3 Topics: Acute Disease; Bone Marrow; Bone Marrow Purging; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cyclophosphamide; Drug Industry; Drug Utilization; Ethics, Medical; Humans; Leukemia, Myeloid; Multicenter Studies as Topic; Neoplasm, Residual; Treatment Outcome; United States; United States Food and Drug Administration	1993
Pharmacological purging of minimal residual disease from peripheral blood stem cell collections of acute myeloblastic leukemia patients: preclinical studies. Experimental hematology, 1997, Volume: 25, Issue:12 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Cyclophosphamide; Etoposide; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Mechlorethamine; Neoplasm, Residual; Tumor Cells, Cultured	1997

Article

Year

Bone marrow purging, 4-hydroperoxycyclophosphamide, and the FDA.

Journal of hematotherapy, 1993,Fall, Volume: 2, Issue:3

Topics: Acute Disease; Bone Marrow; Bone Marrow Purging; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cyclophosphamide; Drug Industry; Drug Utilization; Ethics, Medical; Humans; Leukemia, Myeloid; Multicenter Studies as Topic; Neoplasm, Residual; Treatment Outcome; United States; United States Food and Drug Administration

1993

Pharmacological purging of minimal residual disease from peripheral blood stem cell collections of acute myeloblastic leukemia patients: preclinical studies.

Experimental hematology, 1997, Volume: 25, Issue:12

Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Cyclophosphamide; Etoposide; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Mechlorethamine; Neoplasm, Residual; Tumor Cells, Cultured

1997